Kroger, Albertsons and others allege an unlawful monopoly in one legal case and aim to recover overcharges for a drug in ...

Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the ...

Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.

ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: ...

Takeda forecast annual operating profit to rise 39% to Y475.00 billion. It expects savings from its enterprise-wide efficiency program, significant declines in restructuring expenses and lower ...

TOKYO -- Japanese drugmaker Takeda Pharmaceuticals will invest $30 billion in the U.S. over the next five years, CEO ...

Japanese drugmaker Takeda (TYO: 4502) posted revenue of 4.58 trillion yen ($31.7 billion) for the fiscal year ended March 31, ...

Takeda has shot down candidates acquired in its $525 million Maverick Therapeutics takeover, blowing a hole in its oncology R ...

Takeda’s Julie Kim argues that Trump’s idea to match drug prices to that of other countries could cost the industry up to $1 ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

Share Market Updates - Find here all the updates related to Sensex, Nifty, BSE, NSE, share prices and Indian stock markets ...